Piramal Pharma Ltd Share Price
As on 10 December 2025 at 08:39 IST
Piramal Pharma Ltd. Q1 FY26 Results:
Net loss narrowed to ₹82 crores in Q1 FY26, compared to a net loss of ₹89 crores in Q1 FY25. Total income for the quarter increased 1% year-on-year to ₹1,992 crores, up from ₹1,971 crores.
About Piramal Pharma Ltd
Piramal Pharma Ltd represents a significant force in the Indian pharmaceutical industry. Founded on March 4, 2020, the company has its headquarters in Mumbai. Piramal Pharma has built a notable presence with its global manufacturing footprint. The company’s business model encompasses three main verticals. First, its Contract Development and Manufacturing Organization (CDMO) division provides end-to-end solutions for innovative and generic pharmaceutical companies. Second, the critical care segment specialises in complex hospital generics. Third, the consumer healthcare division delivers over-the-counter products addressing various health needs. Piramal Pharma has built a notable presence in the industry. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-10.64%
Over 6 Months
-17.24%
Over 1 Year
-31.67%
Over 3 Years
34.72%
Piramal Pharma Ltd Summary
Close ₹174.65
Open ₹180.30
High ₹180.30
Low ₹173.40
Volume 30,33,632
Net Turnover (in Cr) ₹53.21
52Wk High ₹273.35
52Wk Low ₹173.40
52Wk High / Low
173.40
273.35
Piramal Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹23,215.32
EPS (TTM) 5.31
Book Value (BV) 58.28
Div. Yield 0.08 %
P/E (TTM) 32.89
Price/Book Value 3
Delivery % 51.48 %
Face Value 10
Key Ratios
PE Ratio 43.01
PB Ratio 3.99
EV to Sales 5.83
PEG Ratio 0.56
ROA 7.91
ROE 9.76
Debt-Equity 0.17
Net Profit Margin 13.08
Operating Profit Margin 23.61
Piramal Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 9,285.99 | 8,346.55 | 7,306.66 | 6,834.90 | 6,479.01 |
| Total Expenses | 8,944.28 | 8,163.96 | 7,474.18 | 6,393.87 | 5,595.43 |
| Profit Before Tax | 414.64 | 179.29 | -120.15 | 484.98 | 949.05 |
| Profit After Tax | 91.13 | 17.82 | -186.46 | 375.96 | 835.03 |
| Operating Profit After Depreciation | 763.30 | 631.08 | 176.66 | 639.28 | 1,047.03 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 8,621.21 | 8,540.03 | 8,034.25 | 7,378.37 | 6,332.61 |
| Total Non Current Assets | 9,880.60 | 9,847.34 | 9,687.08 | 8,729.82 | 7,251.08 |
| Total Current Assets | 5,796.99 | 5,464.47 | 4,835.48 | 4,067.22 | 3,648.70 |
| Total Assets | 15,677.59 | 15,311.81 | 14,522.56 | 12,797.04 | 10,899.78 |
| Total Shareholder's Fund | 8,125.47 | 7,911.37 | 6,773.50 | 6,696.60 | 5,605 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 892.30 | 1,004.54 | 483.89 | 766.42 | 597.58 |
| Net Cash Used In Investing Activities | -488.34 | -416.22 | -1,333.63 | -1,737.40 | -4,464.39 |
| Net Cash Used In Financing Activities | -440.83 | -422.36 | 817.79 | 794.19 | 3,976.83 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 5,493.06 | 4,592.17 | 3,784.29 | 3,565.21 | 3,136.78 |
| Total Expenses | 4,581.92 | 4,084.55 | 3,653.64 | 3,087.80 | 2,468.23 |
| Profit Before Tax | 911.14 | 507.62 | 123.69 | 462.33 | 686.78 |
| Profit After Tax | 691.40 | 391.22 | 69.50 | 367.54 | 571.50 |
| Operating Profit After Depreciation | 1,025.70 | 614.72 | 246.52 | 534.70 | 673.26 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 3,143.90 | 2,913 | 2,881.94 | 2,686.67 | 1,668.47 |
| Total Non Current Assets | 6,855.95 | 6,259.33 | 5,693.72 | 5,268.90 | 3,989.17 |
| Total Current Assets | 3,535.88 | 3,291.55 | 2,348.68 | 2,102.14 | 1,767.50 |
| Total Assets | 10,391.83 | 9,550.88 | 8,042.40 | 7,371.04 | 5,756.67 |
| Total Shareholder's Fund | 7,452.54 | 6,712.07 | 5,261.79 | 5,123.12 | 4,100.62 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 548.77 | 358.29 | 71.52 | 249.19 | 34.72 |
| Net Cash Used In Investing Activities | -551.96 | -635.15 | -435.05 | -1,164.62 | -4,382.89 |
| Net Cash Used In Financing Activities | -61.74 | 451.38 | 290.12 | 896.40 | 4,494.16 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 2,043.72 | 1,933.71 | 2,754.07 | 2,204.22 | 2,241.75 |
| Total Expenses | 1,885.03 | 1,827.01 | 2,193.08 | 1,866.48 | 1,900.14 |
| Profit Before Tax | -46.18 | -79.02 | 272.80 | 66.80 | 120.12 |
| Profit After Tax | -99.22 | -81.70 | 153.50 | 3.68 | 22.59 |
| Operating Profit after Depreciation | 239.08 | 183.67 | 619.24 | 366.92 | 419.98 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,127.26 | 969.88 | 1,689.80 | 1,248.32 | 1,284.39 |
| Total Expenses | 1,000.19 | 925.55 | 1,273.22 | 1,028.98 | 1,031.50 |
| Profit Before Tax | 247.41 | 142.58 | 364.36 | 159.41 | 275.71 |
| Profit After Tax | 196.33 | 113.14 | 277.27 | 118.80 | 210.06 |
| Operating Profit after Depreciation | 329.04 | 225.25 | 456.09 | 244.04 | 359.27 |
Piramal Pharma Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 171.93
S2 169.22
S3 165.03
Pivot 176.12
R1 178.83
R2 183.02
R3 185.73
Moving Average
20 SMA 187.59
50 SMA 193.50
100 SMA 195.90
200 SMA 202.04
Piramal Pharma Ltd Corporate Actions
Piramal Pharma Ltd
₹0.14/Share
Announcement Date 16 Jul 2025
Record Date 16 Jul 2025
Div Yield 1%
Piramal Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,795.30 | ₹4,30,752.61 |
| Divis Laboratories Ltd | ₹6,328.35 | ₹1,67,997.81 |
| Torrent Pharmaceuticals Ltd | ₹3,757.95 | ₹1,27,180.39 |
| Cipla Ltd | ₹1,497.45 | ₹1,20,959.70 |
| Dr Reddys Laboratories Ltd | ₹1,267.15 | ₹1,05,759.02 |
Piramal Pharma Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| HDFC Focused Fund | 2.15% |
| HDFC Flexi Cap Fund | 1.97% |
| HDFC Business Cycle Fund | 1.37% |
| Franklin India Opportunities Fund | 1.01% |
| Canara Robeco Small Cap Fund | 1.01% |
Piramal Pharma Ltd News
Piramal Pharma Ltd down for fifth straight session
Piramal Pharma Ltd is quoting at Rs 193, down 1.25% on the day as on 13:19 IST on the NSE. The stock tumbled 22.98% in last one year as compared to a 7.23% rally in NIFTY and a 0.81% spurt in the Nifty Pharma index.
11 Nov 2025, 01:35 pm
Piramal Pharma reports dismal Q2 numbers
Piramal Pharma reported a consolidated net loss of Rs 99.22 crore in Q2 FY26, compared with a net profit of Rs 22.59 crore recorded in Q2 FY25.
06 Nov 2025, 12:59 pm
Piramal Pharma to discuss results
On 5 November 2025
24 Oct 2025, 02:07 pm
Piramal Pharma Ltd spurts 2.86%, rises for third straight session
Piramal Pharma Ltd is quoting at Rs 202.92, up 2.86% on the day as on 12:49 IST on the NSE. The stock is down 20.68% in last one year as compared to a 6.88% gain in NIFTY and a 0.03% gain in the Nifty Pharma index.
23 Oct 2025, 01:05 pm
Piramal Pharma Solutions opens dedicated OSD form suite at its facility in Sellersville, Pennsylvania
In partnership with NewAmsterdam Pharma
21 Aug 2025, 07:49 pm
Piramal Pharma Ltd Stock Analysis
- Annual revenue for Piramal Pharma Ltd increased by 19.62% to ₹5,493.06 crore in FY 2025 from ₹4,592.17 crore in FY 2024.
- Annual Net Profit for Piramal Pharma Ltd increased by 76.73% to ₹691.40 crore in FY 2025 from ₹391.22 crore in FY 2024.
- Promoter Shareholding in Piramal Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 34.86% in June 2025 to 34.86% in September 2025.
- Piramal Pharma Ltd delivered a 1-year return of -31.67% compared to the Nifty 50, which provided a return of 5.45% as of the last trading session.
- Piramal Pharma Ltd share price moved down by 1.92% from its previous close of INR ₹174.65. The latest Piramal Pharma Ltd share price is INR ₹171.30.
- Piramal Pharma Ltd share price today has been at a low of 170.40 and a high of 174.66. Over the past 52 weeks, the Piramal Pharma Ltd share price has seen a low of 170.40 and a high of 273.35.
About Piramal Pharma Ltd
Piramal Pharma Ltd represents a significant force in the Indian pharmaceutical industry. It operates under the leadership of Chairman Ajay Piramal and the Piramal family. Founded on March 4, 2020, the company has its headquarters in Mumbai.
Piramal Pharma’s business model encompasses three main verticals. First, its Contract Development and Manufacturing Organization (CDMO) division provides end-to-end solutions for innovative and generic pharmaceutical companies. Second, the critical care segment specialises in complex hospital generics. Third, the consumer healthcare division delivers over-the-counter products addressing various health needs.
Piramal Pharma has built a notable presence with its global manufacturing footprint. It is not the largest player in terms of market share or cap. However, the company has earned recognition for its product portfolio and international reach. The Piramal family maintains substantial promoter shareholding (26.62%). This demonstrates their committed involvement in the company’s strategic direction and operations. The registered office is located at Agastya Corporate Park, Mumbai. Meanwhile, the registrar’s office is at Vikhroli.
A team of managerial promoters oversee the company’s operations. They are ● Peter DeYoung ● Vibha Paul Rishi ● Peter Stevenson ● Sridhar Gorthi ● Vivek Valsaraj Piramal Pharma’s success stems from its ability to serve diverse healthcare needs while maintaining high-quality standards. The company’s manufacturing facilities enable it to meet international market demands efficiently. Through its comprehensive healthcare solutions, Piramal Pharma continues to strengthen its position. The company’s integrated approach also positions it as a major player in the global pharmaceutical market.
Piramal Pharma’s commitment to R&D is evident from its substantial investments in this area. The company has established new centres equipped with advanced technology. These facilities are staffed by a team of skilled scientists and researchers. These centres are dedicated to developing new products and improving existing ones. All this ensures that Piramal Pharma remains at the forefront of pharmaceutical innovation.
One of the standout features of Piramal Pharma’s R&D journey is its integrated approach to drug discovery and development. The company offers end-to-end solutions, from the initial stages of drug discovery to the final stages of manufacturing and commercialization. This integrated approach streamlines the development process. It also ensures that the company can quickly bring new and effective drugs to market.
Piramal Pharma has strategically focused its R&D efforts on niche areas where it can leverage its expertise. These include the development of highly potent active pharmaceutical ingredients (HPAPIs), peptide APIs, and complex hospital generics. As a result, the company can offer unique solutions that meet specific market needs.
Collaboration is a key aspect of Piramal Pharma’s R&D strategy. The company has formed strategic partnerships with leading global pharmaceutical companies and universities. This enables Piramal Pharma to access new technology and share knowledge about new drugs. Such partnerships also help the company expand its global footprint and reach new markets.
Quality is at the core of Piramal Pharma’s R&D efforts. The company adheres to stringent quality control measures. It is to ensure that its products meet the highest standards. This commitment to quality has earned Piramal Pharma certifications from various international regulatory bodies. These certifications enhance the company’s credibility. They also open up opportunities in highly regulated markets.
Piramal Pharma’s R&D journey is also characterised by a strong focus on sustainability. The company is committed to developing environmentally friendly processes and products. This includes reducing waste and minimising the environmental impact of its operations. By integrating sustainability into its R&D efforts, Piramal Pharma contributes to a healthier planet. It also meets the growing demand for sustainable pharmaceutical solutions.
The company’s R&D efforts are complemented by its advanced manufacturing capabilities. Piramal Pharma has invested in new facilities that can produce various pharmaceutical products. They are equipped to handle complex formulations. This ensures that the company can meet the diverse needs of its customers.
Piramal Pharma’s R&D journey is marked by a culture of continuous improvement. The company regularly reviews its processes and practices to identify areas for enhancement. This commitment to continuous improvement drives operational excellence. It also ensures that Piramal Pharma remains competitive in a rapidly evolving industry.
Piramal Pharma’s R&D efforts have a global impact. The company serves a diverse client base that includes big and generic pharmaceutical companies. Its products are distributed in over 100 countries, supported by a strong sales presence in key markets such as the US, UK, Italy, and Germany. This global reach enhances the company’s market presence. It also provides valuable insights into emerging trends and customer needs. Looking ahead, Piramal Pharma is poised to continue its journey of innovation. The company plans to further expand its R&D capabilities and leverage emerging technologies such as AI and machine learning. As a result, Piramal Pharma aims to develop breakthrough solutions that address unmet medical needs.
Piramal Pharma’s business model encompasses three main verticals. First, its Contract Development and Manufacturing Organization (CDMO) division provides end-to-end solutions for innovative and generic pharmaceutical companies. Second, the critical care segment specialises in complex hospital generics. Third, the consumer healthcare division delivers over-the-counter products addressing various health needs.
Piramal Pharma has built a notable presence with its global manufacturing footprint. It is not the largest player in terms of market share or cap. However, the company has earned recognition for its product portfolio and international reach. The Piramal family maintains substantial promoter shareholding (26.62%). This demonstrates their committed involvement in the company’s strategic direction and operations. The registered office is located at Agastya Corporate Park, Mumbai. Meanwhile, the registrar’s office is at Vikhroli.
A team of managerial promoters oversee the company’s operations. They are ● Peter DeYoung ● Vibha Paul Rishi ● Peter Stevenson ● Sridhar Gorthi ● Vivek Valsaraj Piramal Pharma’s success stems from its ability to serve diverse healthcare needs while maintaining high-quality standards. The company’s manufacturing facilities enable it to meet international market demands efficiently. Through its comprehensive healthcare solutions, Piramal Pharma continues to strengthen its position. The company’s integrated approach also positions it as a major player in the global pharmaceutical market.
Innovation in Action - Piramal’s R&D Journey
Piramal Pharma Ltd has carved a niche for itself in the pharmaceutical industry through its relentless focus on research and development. This journey of innovation is marked by several key initiatives and strategies that have helped Piramal Pharma stay ahead in a competitive market.Piramal Pharma’s commitment to R&D is evident from its substantial investments in this area. The company has established new centres equipped with advanced technology. These facilities are staffed by a team of skilled scientists and researchers. These centres are dedicated to developing new products and improving existing ones. All this ensures that Piramal Pharma remains at the forefront of pharmaceutical innovation.
One of the standout features of Piramal Pharma’s R&D journey is its integrated approach to drug discovery and development. The company offers end-to-end solutions, from the initial stages of drug discovery to the final stages of manufacturing and commercialization. This integrated approach streamlines the development process. It also ensures that the company can quickly bring new and effective drugs to market.
Piramal Pharma has strategically focused its R&D efforts on niche areas where it can leverage its expertise. These include the development of highly potent active pharmaceutical ingredients (HPAPIs), peptide APIs, and complex hospital generics. As a result, the company can offer unique solutions that meet specific market needs.
Collaboration is a key aspect of Piramal Pharma’s R&D strategy. The company has formed strategic partnerships with leading global pharmaceutical companies and universities. This enables Piramal Pharma to access new technology and share knowledge about new drugs. Such partnerships also help the company expand its global footprint and reach new markets.
Quality is at the core of Piramal Pharma’s R&D efforts. The company adheres to stringent quality control measures. It is to ensure that its products meet the highest standards. This commitment to quality has earned Piramal Pharma certifications from various international regulatory bodies. These certifications enhance the company’s credibility. They also open up opportunities in highly regulated markets.
Piramal Pharma’s R&D journey is also characterised by a strong focus on sustainability. The company is committed to developing environmentally friendly processes and products. This includes reducing waste and minimising the environmental impact of its operations. By integrating sustainability into its R&D efforts, Piramal Pharma contributes to a healthier planet. It also meets the growing demand for sustainable pharmaceutical solutions.
The company’s R&D efforts are complemented by its advanced manufacturing capabilities. Piramal Pharma has invested in new facilities that can produce various pharmaceutical products. They are equipped to handle complex formulations. This ensures that the company can meet the diverse needs of its customers.
Piramal Pharma’s R&D journey is marked by a culture of continuous improvement. The company regularly reviews its processes and practices to identify areas for enhancement. This commitment to continuous improvement drives operational excellence. It also ensures that Piramal Pharma remains competitive in a rapidly evolving industry.
Piramal Pharma’s R&D efforts have a global impact. The company serves a diverse client base that includes big and generic pharmaceutical companies. Its products are distributed in over 100 countries, supported by a strong sales presence in key markets such as the US, UK, Italy, and Germany. This global reach enhances the company’s market presence. It also provides valuable insights into emerging trends and customer needs. Looking ahead, Piramal Pharma is poised to continue its journey of innovation. The company plans to further expand its R&D capabilities and leverage emerging technologies such as AI and machine learning. As a result, Piramal Pharma aims to develop breakthrough solutions that address unmet medical needs.
FAQ’s
What is the share price of Piramal Pharma Ltd today?
Piramal Pharma Ltd share price as on 10 Dec 2025 is ₹ 171.3
What is the Market Cap of Piramal Pharma Ltd?
The market cap of Piramal Pharma Ltd stock is ₹23,215.32 Cr.
What is the PE Ratio of Piramal Pharma Ltd?
The Price to Earnings (P/E) Ratio of Piramal Pharma Ltd is 43.01
What is the PB Ratio of Piramal Pharma Ltd?
The Price to Book (P/B) Ratio of Piramal Pharma Ltd is 3.99
What is the 52 week high of Piramal Pharma Ltd Share Price?
The 52 week high of Piramal Pharma Ltd share price stands at ₹273.35
What is the 52 week low of Piramal Pharma Ltd Share Price?
The 52 week low of Piramal Pharma Ltd share price stands at ₹173.40
How can I buy shares of Piramal Pharma Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Piramal Pharma Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
